SDC1 and plasma cell myeloma: Of note, the proteasomal inhibitor bortezomib, which is used in the clinic to prevent transcription factor activation (e.g. NF- κB) in multiple myeloma cells, causes the accumulation of the syndecan-1 cCTF in tumor cells [14].